| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01809171 2013-001064-27 Details | 2015-10-21 Interventional | 2/3 | 15 | Cholecalciferol Vitamin D Breast Neoplasm… Musculoskeletal… Breast Cancer Musculoskeletal… | Inclusion problems - | |||
| NCT01042028 Details | 2015-10-20 Interventional | 1/2 | 39 | Capecitabine Cetuximab Everolimus Irinotecan Oxaliplatin Pancreatic Neop… Pancreatic Canc… | Emergence of FOLFIRINOX and slow recruitment - | |||
| NCT00272909 Details | 2015-10-20 Interventional | 2 | 43 | Piclozotan Ischemic Stroke Stroke | - - | |||
| NCT00437073 Details | 2015-10-15 Interventional | 2 | 22 | Capecitabine Lapatinib Topotecan Brain Neoplasms Breast Neoplasm… Neoplasm Metast… Neoplasms, Brea… | Lapatinib-topotecan arm enrollment closed early per protocol amendment 2. Then enrollment into
remaining arm terminated due to operational issues. - | |||
| NCT00428168 Details | 2015-10-15 Interventional | 2 | 36 | Betahistine Body Weight Weight Gain | Interim Analysis result indicated the study will not show a significant benefit of the study
medication on the primary endpoint. - | |||
| NCT00360867 Details | 2015-10-15 Interventional | 2 | 94 | Imetelstat Motesanib dipho… Solid Tumors | Amgen decision - | |||
| NCT00356681 Details | 2015-10-15 Interventional | 2 | 282 | Bevacizumab Imetelstat Motesanib dipho… Niacinamide Paclitaxel Breast Neoplasm… Breast Cancer Breast Tumors Locally Recurre… | Sponsor decision to close study - | |||
| NCT00031837 Details | 2015-10-14 Interventional | 3 | - | Dalteparin Gemcitabine Heparin, Low-Mo… Tinzaparin Pancreatic Neop… Thromboembolism Pancreatic Canc… | - - | |||
| NCT02197286 Details | 2015-10-12 Interventional | 2 | 0 | Cholecalciferol Ergocalciferols Vitamin D Vitamins Psychotic Disor… Schizophrenia Schizoaffective… | Personnel changes at study site. - | |||
| NCT01546883 Details | 2015-10-12 Interventional | 4 | 14 | Dabigatran Atrial Fibrilla… | Not enough patients in time period allotted for study - | |||
| NCT00890890 2009-010067-16 Details | 2015-10-12 Interventional | 2 | 263 | BMS 708163 Alzheimer Disea… Alzheimer's Dis… | - - | |||
| NCT00850577 2008-007768-41 Details | 2015-10-12 Interventional | 2 | 255 | Bevacizumab Carboplatin Paclitaxel Pharmaceutical … Carcinoma, Non-… Lung Neoplasms Non-small Cell … | - - | |||
| NCT00805311 Details | 2015-10-12 Interventional | 4 | [1 Refs] | 400 | Amlodipine Aspirin Atorvastatin Losartan Atherosclerosis Carotid Stenosi… Constriction, P… Carotid Artery … Stroke | Due to the clear advantage of carotid endarterectomy - | ||
| NCT01868243 Details | 2015-10-09 Interventional | 2/3 | 27 | Dabigatran Warfarin Atrial Fibrilla… Primary Disease | because a significant decrease of viable candidates for the study. - | |||
| NCT01751802 Details | 2015-10-08 Interventional | 3 | 9 | Ecopipam Lesch-Nyhan Syn… Self-Injurious … Lesch-Nyhan Dis… Self-injurious … | Study terminated for commercial reasons - | |||
| NCT00591019 Details | 2015-10-08 Interventional | 1 | 7 | Modafinil Tinnitus | Terminated early due to lack of change in primary and secondary outcome measures. Study was terminated early due to lack of change in primary and secondary outcome measures. | |||
| NCT00469976 Details | 2015-10-08 Interventional | 2 | 0 | Bevacizumab Carboplatin Gemcitabine Carcinoma, Non-… Lung Neoplasms Lung Cancer | ECOG will not proceed with activation - | |||
| NCT01887457 2013-002578-34 Details | 2015-10-07 Interventional | 2 | - | Voriconazole Aspergillosis Fusarium Immunocompromis… | Transfer of management of study - | |||
| NCT02307591 Details | 2015-10-06 Interventional | 2/3 | 0 | Amiodarone Hemorrhagic Fev… Virus Diseases Ebola Virus Dis… | The Study could not be started due to an insufficient number of new EVD cases. - | |||
| NCT00093652 Details | 2015-10-06 Interventional | 1/2 | [1 Refs] | - | Gefitinib Oxaliplatin Esophageal Neop… Esophageal Canc… | - - |